BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT00289640
- Locations
- 🇺🇸
Center For Oncology Research & Treatment, P.A., Dallas, Texas, United States
🇺🇸Oncology Specialists, Sc, Park Ridge, Illinois, United States
🇺🇸St Joseph Oncology Inc, St Joseph, Missouri, United States
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 155
- Registration Number
- NCT00289627
- Locations
- 🇺🇦
Local Institution, Uzhgorod, Ukraine
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
- Conditions
- Psoriasis Vulgaris
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 144
- Registration Number
- NCT00287547
- Locations
- 🇺🇸
Local Institution, Burlington, Vermont, United States
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT00284804
- Locations
- 🇺🇸
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
🇺🇸California Oncology of the Central Valley, Fresno, California, United States
🇺🇸American Health Network of Indiana, Indianapolis, Indiana, United States
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT00279760
- Locations
- 🇬🇧
Local Institution, Leeds, United Kingdom
🇧🇪Local Instiution, Bruxelles, Belgium
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Tetanus + pnemococcal vaccines alone
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00279734
- Locations
- 🇺🇸
Qutintiles Phase I Services, Lenexa, Kansas, United States
🇺🇸PPD Development, Austin, Texas, United States
🇺🇸Parexel International Corp, Baltimore, Maryland, United States
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
- Conditions
- Psoriasis Vulgaris
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT00277225
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Beverly Hills, California, United States
Comparability DE vs CD-CHO1
- Conditions
- Healthy Subjects
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00277199
- Locations
- 🇬🇧
Inveresk Clinical Research, Edinburgh, United Kingdom
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1057
- Registration Number
- NCT00272779
- Locations
- 🇬🇧
Local Institution, Manchester, Greater Manchester, United Kingdom
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
- Conditions
- Unresectable Stage III or IV Malignant Melanoma
- Interventions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00261365
- Locations
- 🇺🇸
Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸The Angeles Clinic And Research Institution, Santa Monica, California, United States
🇸🇪Local Institution, Stockholm, Sweden